Cancer Gene Therapy Market to Reach $2,082.5 Mn, Globally, by 2023

High prevalence of cancer worldwide, increase in geriatric population, and growing funding from governmental and non-governmental organizations for R&D drive the growth of the global cancer gene therapy market. Gene transfer segment to manifest the fastest growth through the forecast period. Among regions, the market in North America would grab the largest market share and the Asia-Pacific market would grow at the fastest CAGR through 2023.

Pune, INDIA


Portland, OR, May 08, 2019 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global cancer gene therapy market garnered $385.8 million and is likely to accrue a sum of $2,082.5 million by 2023, registering a CAGR of 32.4% through 2023. The report provides a thorough analysis of the market dynamics, top winning strategies, key market segments, top investment pockets, and competitive landscape.

Request Report Sample at: https://www.alliedmarketresearch.com/request-sample/2605

High prevalence of incidence of cancer, surge in geriatric population, and increase in funding from governmental and non-governmental organizations for R&D drive the growth of the global cancer gene therapy market. However, high cost for gene therapy and adverse effects such as immune response hamper the market growth. On the contrary, increase in the adoption of cancer gene therapy due to technological advancements and high growth potential in the untapped markets in the developing countries such as India and China would create lucrative opportunities for the market.

The gene transfer segment is likely to see the fastest CAGR of 32.8% during the forecast period. This is due to the increase in funding for the development of gene transfer therapy to effectively treat cancer. Nonetheless, oncolytic virotherapy therapy segment was the largest in 2017, capturing over 43% share of the market share.

In 2017, the market in North America was the largest, grabbing more than half of the total market share owing to increase in the number of viral infection cases and high prevalence of cancer and other inherited disorders in the region. However, the Asia-Pacific market is likely to show the fastest CAGR of 38.4% through 2023. This is due to several government initiatives to improve the healthcare infrastructure in developing economies. The other regions analyzed in the report include Europe and Latin America, Middle East and Africa (LAMEA).

Do Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2605

The players operating in the global cancer gene therapy market include Adaptimmune, bluebird bio, Inc., Celgene, BioCancell, SynerGene Therapeutics, GlaxoSmithKline, Merck, Shanghai Sunway Biotech, Shenzhen SiBiono GeneTech, and OncoGenex Pharmaceuticals.

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.


        

Contact Data